List of Excipients in Branded Drug COSMEGEN

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Recordati Rare Diseases Inc	COSMEGEN	dactinomycin	55292-811	MANNITOL

Last updated: August 21, 2026

Executive summary: Cosmegen is the branded U.S. formulation of dactinomycin, an old cytotoxic injectable with a simple lyophilized composition centered on mannitol. Its core composition and active-ingredient protection do not create a meaningful modern exclusivity barrier. Commercial value lies in formulation execution: ready-to-use presentations, safer hazardous-drug handling, improved stability, hospital workflow, supply reliability, and differentiated packaging. The most defensible opportunities are likely to arise from device, container-closure, process, and method-of-use claims rather than from a conventional excipient patent on dactinomycin itself.

COSMEGEN Excipient Strategy and Commercial Opportunities for Dactinomycin

What is Cosmegen and how is it formulated?

Cosmegen contains dactinomycin, also known as actinomycin D, a cytotoxic antineoplastic antibiotic used in Wilms tumor, rhabdomyosarcoma, gestational trophoblastic neoplasia, and other oncology indications. The U.S. product is supplied as a sterile lyophilized powder for intravenous administration in a 0.5 mg vial.[1]

The labeled composition is commercially simple:

Product attribute	Cosmegen profile
Active ingredient	Dactinomycin
Strength	0.5 mg per vial
Dosage form	Sterile lyophilized powder for injection
Primary excipient	Mannitol
Route	Intravenous
Preservative	Not identified in the labeled formulation
Reconstitution	Sterile water for injection, according to product labeling
Handling	Cytotoxic and hazardous-drug precautions apply
FDA regulatory pathway	Approved new drug application
Biosimilar classification	Not applicable

Mannitol functions primarily as a bulking agent and contributes to cake formation during lyophilization. The formulation does not depend on a complex surfactant, lipid, polymer, or pH-buffer system. That simplicity reduces development burden but also limits the ability to create a strong composition-of-matter patent around a new excipient combination.

The central formulation challenge is not solubilizing a high-dose conventional small molecule. It is preserving a potent, cytotoxic drug in a low-dose sterile product that must tolerate manufacturing, storage, reconstitution, withdrawal, dilution, and administration.

What excipients protect Cosmegen?

The principal labeled excipient is mannitol. Its commercial functions include:

1. Providing lyophilized cake structure.
2. Controlling the solids content of the vial.
3. Supporting acceptable appearance after freeze-drying.
4. Helping produce a product that can be reconstituted for intravenous use.

Mannitol is widely used in injectable lyophilized products. It is generally considered a familiar excipient for FDA regulatory purposes, which can simplify justification of its use. That familiarity also weakens exclusivity prospects. A patent covering mannitol as a bulking agent in dactinomycin is likely to face substantial novelty and obviousness challenges unless it captures an unexpected stability, reconstitution, or manufacturing result.

Which excipient attributes matter most?

For Cosmegen-type products, the highest-value excipient attributes are:

Attribute	Commercial relevance
Low endotoxin burden	Required for parenteral oncology products
Low particulate generation	Important for IV administration and inspection
Lyophilization compatibility	Affects cake integrity, collapse, and reconstitution
Low interaction with dactinomycin	Supports potency and impurity control
Low container adsorption	Protects dose recovery at microgram-to-milligram concentrations
Compatibility with hazardous-drug handling	Reduces occupational and administration risk
Reliable global supply	Important because injectable oncology shortages can interrupt treatment

A reformulation strategy should evaluate excipients as part of the full container-closure and manufacturing system. Vial glass, stopper elastomer, residual moisture, headspace, reconstitution solvent, and transfer devices may affect product performance as much as the excipient itself.

What formulation patents could protect a Cosmegen reformulation?

The most commercially credible patent targets are platform claims tied to measurable performance rather than broad claims to dactinomycin plus a familiar excipient.

Lyophilized formulations

Potential claim areas include:

• A defined dactinomycin-to-mannitol ratio.
• A specified residual-moisture range.
• A lyophilization cycle that limits degradation products.
• A reconstitution time below a defined threshold.
• A formulation that reduces visible or subvisible particles.
• A vial presentation with improved dose recovery.
• A product with a defined impurity profile after accelerated storage.

A patent applicant would need comparative data against the existing Cosmegen composition and generic products. Merely substituting sucrose, trehalose, lactose, glycine, or another standard bulking agent would face predictable obviousness arguments.

Liquid or ready-to-use formulations

A liquid dactinomycin product could create a more valuable commercial proposition because it would remove pharmacy reconstitution. The technical risks are higher:

• Chemical degradation during shelf life.
• Adsorption to the primary container or administration set.
• Light sensitivity.
• pH-dependent instability.
• Increased impurity formation.
• Sterility and particulate-control requirements.
• Greater consequences from accidental handling or leakage.

A successful ready-to-use product could support patents covering a defined pH range, stabilizer system, container material, oxygen-control strategy, or shelf-life performance. It could also support a 505(b)(2) development program if the formulation materially differs from the approved lyophilized product.[2]

Reconstitution and administration systems

Device and packaging claims may be stronger than excipient-only claims. Possible products include:

• A single-use vial adapter that limits aerosolization.
• A closed-system transfer device designed for dactinomycin.
• A dual-chamber container holding diluent separately from lyophilized drug.
• A prefilled syringe or cartridge for controlled transfer.
• A light-protective secondary package.
• A dose-preparation kit with validated compatibility to infusion materials.

These products can target hospital pharmacy labor, occupational exposure, medication-error reduction, and waste. They also create licensing opportunities with injectable-drug manufacturers and medical-device companies.

How strong is the Cosmegen patent estate?

Cosmegen has limited prospective patent value as a legacy drug. Dactinomycin was approved decades ago, and the original active-ingredient, formulation, and use patents would have expired long ago. The principal commercial barrier is therefore regulatory execution, manufacturing capability, hazardous-drug handling, and supply reliability rather than basic patent exclusivity.

What is the Orange Book status of Cosmegen?

The FDA Orange Book identifies approved drug products and applicable patent and exclusivity information. Cosmegen is associated with an older NDA for dactinomycin injection. The Orange Book record does not provide a modern, unexpired patent barrier that would prevent an ANDA applicant from pursuing a conventional dactinomycin injection product.[3]

The practical implications are:

Issue	Cosmegen assessment
Active-ingredient patent	Expired
Original formulation protection	Expired
Regulatory exclusivity	Expired
Current Orange Book patent barrier	No material listed barrier identified
Paragraph IV exposure	Relevant to any later-listed patent, but not central to the legacy product
Biosimilar risk	Not applicable
ANDA competition	Legally available
505(b)(2) opportunity	Possible for a materially different formulation or presentation

A later reformulation patent could create a new patent dispute, but it would not restore exclusivity to the unmodified dactinomycin product. Its enforceability would depend on claim scope, clinical relevance, non-obviousness, and whether generic products practice the claimed formulation or method.

When does Cosmegen lose exclusivity?

Cosmegen has already lost the exclusivity associated with its original approval. There is no meaningful remaining period of new-drug exclusivity for the legacy formulation. The product competes in a mature generic market, subject to FDA approval, manufacturing capacity, product quality, and procurement dynamics.

The relevant timing distinction is between:

• The legacy dactinomycin product, which has no meaningful remaining originator exclusivity.
• A new formulation, which could receive separate regulatory exclusivity if it satisfies the requirements of the applicable FDA pathway.
• A new method of use, which could support use-specific patent protection but would not necessarily block all generic dactinomycin use.
• A device or combination product, which could create separate patent rights but may not prevent substitution of the underlying drug.

What generic entry risks exist for Cosmegen?

Generic entry risk is high for the conventional lyophilized vial. A generic applicant can pursue an ANDA if it can demonstrate pharmaceutical equivalence, bioequivalence where applicable, and compliance with manufacturing and quality requirements.[2]

Paragraph IV challenges

A Paragraph IV certification becomes relevant if an applicant seeks approval while challenging an unexpired listed patent. For the legacy Cosmegen formulation, the absence of a material current Orange Book patent barrier reduces the importance of Paragraph IV litigation.

A reformulated product could generate Paragraph IV risk if its patent is listed and a generic applicant seeks to market a product that falls within the claims. The strongest litigation positions would usually involve:

• Narrow, experimentally supported composition ranges.
• Specific stability outcomes.
• Defined container-closure combinations.
• Validated manufacturing parameters.
• A patented method of reducing hazardous-drug exposure or preparation time.

Broad claims to dactinomycin with a conventional sugar or polyol excipient would be more vulnerable.

Generic launch scenarios

Scenario	Likely commercial effect
Additional conventional lyophilized generics	Price pressure and tender competition
Generic product with reliable supply	Reduced brand leverage in hospitals
Shortage among generic suppliers	Temporary demand for branded or alternate supply
Ready-to-use reformulation	Potential premium pricing and workflow differentiation
Closed-system presentation	Possible hospital preference despite higher unit cost
New indication or dosing method	Narrower market protection and limited substitution impact

What commercial opportunities exist in Cosmegen excipients?

The largest opportunities are not likely to come from selling mannitol. They are likely to come from improving the product system around mannitol-based dactinomycin.

1. Ready-to-use injectable product

A stable liquid or reconstituted presentation could command a premium if it reduces pharmacy preparation. The value proposition is strongest in hospitals with high hazardous-drug throughput, constrained pharmacy staffing, or strict closed-system-transfer requirements.

The product would need a clear advantage in shelf life, dose recovery, preparation time, or safety. A liquid formulation that merely eliminates reconstitution but requires refrigerated storage or has a short expiry may not generate sufficient economic value.

2. Improved lyophilized formulation

A next-generation cake could preserve the existing regulatory familiarity of a lyophilized vial while improving:

• Reconstitution speed.
• Residual-volume recovery.
• Resistance to shipping stress.
• Visual quality.
• Stability after reconstitution.
• Compatibility with automated compounding systems.

This is the lowest-risk formulation opportunity because it builds on the established dosage form.

3. Closed-system transfer and pharmacy workflow

Dactinomycin is hazardous. A product designed for safer preparation could compete on total treatment cost rather than vial price. Relevant commercial metrics include:

• Pharmacy preparation minutes saved per dose.
• Reduction in transfer steps.
• Reduction in drug waste.
• Compatibility with automated compounding.
• Decreased risk of accidental exposure.
• Lower frequency of preparation-related errors.

A combination of drug, vial adapter, transfer device, and validated instructions could support a differentiated product even when the active ingredient is generic.

4. Container-closure and low-sorption technology

At low drug concentrations, adsorption and extractables can affect dose delivery and quality. A differentiated vial or syringe system may support claims around:

• Surface treatment.
• Elastomer selection.
• Silicone control.
• Low-binding polymer components.
• Improved dose recovery.
• Reduced particulate formation.

These claims can create a defensible IP position if supported by head-to-head recovery and stability data.

5. Global supply and contract manufacturing

Dactinomycin is a specialized sterile cytotoxic product. Manufacturing barriers can be more important than patent barriers. A supplier with validated containment, lyophilization capacity, and dependable sterile fill-finish may capture value through:

• Contract manufacturing.
• Regional licensing.
• Hospital supply agreements.
• Authorized generic arrangements.
• Dual-source procurement programs.

The main risk is limited market size. Cosmegen revenue is not separately disclosed in public financial reporting, so product-specific revenue exposure cannot be reliably quantified from company filings.

How does Cosmegen compare with other oncology injectables?

Cosmegen differs from complex biologic oncology products because it has no biosimilar pathway and does not depend on a large molecular structure or immunogenicity program. It resembles older generic cytotoxics in that manufacturing quality, sterile supply, and hospital purchasing have greater commercial importance than active-ingredient patents.

Category	Cosmegen	Biologic oncology product	Conventional generic cytotoxic
Molecule	Small-molecule antibiotic	Biologic	Small molecule
Biosimilar pathway	No	Yes	No
Core patent value	Low for legacy product	Often high	Usually low
Excipient complexity	Low to moderate	Often high	Variable
Manufacturing barrier	Sterile cytotoxic containment	Bioprocessing and aseptic fill	Sterile manufacturing
Differentiation opportunity	Presentation and workflow	Formulation, device, delivery	Cost, supply, presentation
Hospital purchasing sensitivity	High	High	High

What geographic coverage and licensing opportunities exist?

The United States is governed by FDA approval, Orange Book listings, and state and federal hazardous-drug requirements. Outside the United States, protection and approval depend on national registrations, local patent registers, procurement systems, and manufacturing standards.

Potential licensing structures include:

• A formulation license for a stabilized liquid product.
• A device license for closed-system preparation.
• A regional commercialization agreement.
• An authorized generic arrangement.
• A contract manufacturing and supply agreement.
• A co-development deal for a new indication or administration system.

A licensee would likely value reliable sterile manufacturing and regulatory history more than a broad excipient patent. Geographic exclusivity could be commercially useful in markets where injectable cytotoxic supply is concentrated among few suppliers.

What is the investment case for Cosmegen excipient innovation?

The opportunity is selective rather than broad. A conventional mannitol substitution is unlikely to produce durable value. A product that reduces preparation time, improves safety, or solves supply and stability problems has a stronger business case.

The best development profile would combine:

1. A measurable hospital workflow benefit.
2. A formulation that remains compatible with established dactinomycin use.
3. A patentable container, device, or stability feature.
4. A manageable FDA pathway.
5. A supply advantage in sterile cytotoxic manufacturing.

A reformulation without a clear operational benefit would face generic price competition. A differentiated presentation could support premium pricing, but adoption would depend on formulary decisions, pharmacy economics, and evidence that the new product reduces total administration cost.

Key Takeaways

• Cosmegen is a 0.5 mg lyophilized dactinomycin injection with mannitol as the principal labeled excipient.[1]
• The legacy product has no meaningful remaining originator exclusivity or modern patent barrier.
• Conventional excipient substitution is unlikely to create strong commercial protection.
• The strongest opportunities are ready-to-use presentations, improved lyophilization, closed-system transfer, low-sorption packaging, and hazardous-drug workflow solutions.
• Cosmegen is not subject to biosimilar competition because dactinomycin is a small molecule.
• Generic entry risk is high for the conventional vial.
• A new product would need measurable advantages in stability, preparation time, dose recovery, safety, or supply reliability.
• Commercial revenue for Cosmegen is not separately disclosed, limiting product-specific revenue analysis.
• Manufacturing capability and hospital procurement may matter more than patent ownership.

FAQs

Can mannitol be replaced in a dactinomycin formulation?

Yes, but a replacement such as sucrose, trehalose, glycine, or another bulking agent would require comparative development work covering stability, cake structure, reconstitution, impurities, and intravenous compatibility. Familiar excipient status alone would not create commercial differentiation.

Could a ready-to-use Cosmegen product receive new FDA exclusivity?

Potentially. A materially different formulation could use a 505(b)(2) pathway and may qualify for regulatory exclusivity if it satisfies statutory requirements. Any exclusivity would attach to the new product or approved change, not automatically to all dactinomycin products.[2]

Is there a biosimilar threat to Cosmegen?

No. Dactinomycin is a small-molecule drug. Competing products would generally use the generic drug approval framework rather than the biosimilar pathway.

Can a closed-system transfer device be patented for dactinomycin?

Yes, if the claims cover a novel device, compatibility configuration, preparation method, or measurable exposure-reduction result. A generic device claim that merely applies known transfer technology to dactinomycin would face validity and infringement challenges.

What is the most attractive commercial formulation opportunity?

A stable, pharmacy-ready presentation with validated hazardous-drug handling and strong dose recovery is the leading opportunity. Its value would come from reducing preparation labor and exposure risk rather than from the mannitol excipient itself.

References

1. Merck Sharp & Dohme LLC. (n.d.). Cosmegen (dactinomycin for injection) prescribing information. U.S. Food and Drug Administration/DailyMed.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.

3. U.S. Food and Drug Administration. (2024). Electronic Orange Book: Dactinomycin, NDA 050682. U.S. Department of Health and Human Services.